Pharming Group has secured FDA Priority Review for lower doses of Joenja in children with activated PI3K delta syndrome, potentially extending the targeted therapy to patients aged four years and older who weigh between 13 and 27 kilograms. The supplemental New Drug Application has a January 30, 2027 target action date and follows the recent expansion of Joenja to children weighing at least 27 kilograms, meaning approval could make the medicine available across a substantially broader pediatric weight range. The application is supported by positive Phase III pediatric results together with additional clinical pharmacology evidence intended to establish appropriate exposure at lower body weights.
The regulatory milestone is particularly relevant because lower-weight dosing was the central issue that complicated Pharming Group’s original pediatric expansion. The FDA previously questioned whether smaller children could achieve drug exposure comparable with the approved adolescent and adult regimen, prompting Pharming Group to separate the pediatric filing into weight-based regulatory packages. The latest acceptance suggests the agency now has enough information to formally review the lower-dose strategy, although Priority Review does not indicate that approval is assured.
Lower-dose Joenja filing addresses the pediatric exposure question raised during the earlier FDA review
Joenja, or leniolisib, is an oral selective PI3K delta inhibitor designed to address the molecular defect underlying activated PI3K delta syndrome, commonly known as APDS. The disease results from pathogenic variants in PIK3CD or PIK3R1 that produce excessive PI3K delta signaling, disrupting normal immune-cell development and function. Patients can experience recurrent respiratory infections, enlarged lymphoid organs, autoimmunity and gastrointestinal complications, while progressive disease can contribute to permanent lung injury and an increased risk of lymphoma.
The FDA initially approved Joenja for patients aged 12 years and older in 2023. Pharming Group subsequently pursued pediatric expansion using an open-label Phase III study in children aged four to 11 years, but the original supplemental application received a Complete Response Letter after regulators raised concerns that lower-weight patients could be underexposed at the proposed doses. The agency also requested clarification regarding an analytical method used for production-batch testing.
Pharming Group responded by separating the weight groups. The company resubmitted doses covering children weighing at least 27 kilograms, and the FDA recently approved 40-milligram and 50-milligram twice-daily dosing for that population. The latest application now addresses children weighing between 13 and 27 kilograms using lower doses supported by additional scientific and clinical pharmacology assessments.
That sequence makes the new review an important test of whether Pharming Group has fully resolved the exposure concern identified in the earlier regulatory process. Approval would effectively complete the company’s intended United States pediatric expansion for eligible patients aged four and older weighing at least 13 kilograms.
Pediatric Phase III data showed improvement in two biological hallmarks of APDS
The lower-dose application uses evidence from the same multinational Phase III pediatric program that supported the heavier-weight expansion. The open-label, single-arm study enrolled 21 children aged four to 11 years and evaluated leniolisib across four weight-adjusted dose levels. All participants completed the initial 12-week treatment period.
Two principal biological measures improved during treatment. Investigators observed reductions in lymphadenopathy, reflecting a decrease in abnormal lymph-node enlargement, together with increases in the proportion of naïve B cells. Those changes are relevant because APDS produces both excessive lymphoid proliferation and abnormal immune-cell maturation, meaning improvement across the two measures provides evidence that leniolisib is affecting the underlying disease biology rather than simply treating individual symptoms.
The pediatric improvements were observed across the four studied doses and were described as consistent with findings previously reported in adolescents and adults. Earlier safety reporting showed treatment-emergent adverse events were mild or moderate, no drug-related serious adverse events were identified and all participants completed the 12-week primary treatment period.
The current FDA release does not provide new quantitative efficacy results specifically for children weighing between 13 and 27 kilograms. The regulatory question is therefore focused less on whether leniolisib demonstrates biological activity in younger patients and more on whether the proposed lower dosing can reliably produce appropriate drug exposure while maintaining the established safety profile.
Priority Review could close one of the remaining gaps in Joenja’s expanding global pediatric label
APDS is extremely rare, affecting an estimated one to two people per million worldwide, and diagnosis can be difficult because its recurrent infections and immune abnormalities overlap with other primary immunodeficiencies. Published evidence cited by Pharming Group indicates patients may experience a median diagnostic delay of about seven years, potentially allowing irreversible complications to accumulate before targeted treatment begins.
Earlier treatment could therefore have particular relevance in pediatric disease. Joenja directly inhibits hyperactive PI3K delta signaling rather than relying entirely on antibiotics, immunoglobulin replacement or other measures used to manage consequences of immune dysfunction.
The United States label already covers patients aged four and older weighing at least 27 kilograms following the recent FDA expansion. Japan has approved Joenja for patients aged four and older without the same United States weight restriction, while approvals in Europe, Canada, South Korea and several other markets currently cover older patients.
A positive January decision would therefore align more of the United States pediatric population with the broader treatment ambition already being pursued internationally. It would also remove a regulatory issue that has followed the pediatric program since the Complete Response Letter earlier in the year.
Joenja is becoming increasingly important to Pharming Group as revenue grows beyond RUCONEST
The label expansion also matters financially because Joenja is becoming a larger contributor to Pharming Group’s business. Second-quarter Joenja revenue reached $17.9 million, up 40% from a year earlier, while first-half revenue increased 37% to $32 million. The United States accounted for 86% of second-quarter Joenja sales, making additional eligible American patients commercially meaningful despite the rarity of APDS.
Pharming Group reported 132 patients on paid Joenja therapy in the United States at the end of June, up 16% from a year earlier. The company had identified 1,042 diagnosed APDS patients globally, including 298 in the United States, with 60 identified American patients between four and 11 years of age at that point. The company has not disclosed how many of those children fall specifically within the 13-to-27-kilogram weight group covered by the new filing, so the incremental commercial population cannot yet be quantified precisely.
The growing Joenja franchise is particularly important because Pharming Group’s older RUCONEST business has faced pressure. Second-quarter RUCONEST revenue fell 10% year over year to $72.3 million, contributing to a 3% decline in total quarterly revenue to $90.2 million. Pharming Group nevertheless maintained expectations for accelerating Joenja growth while revising full-year total revenue guidance to $375 million to $395 million.
Cash, restricted cash and marketable securities totaled $159.5 million at the end of June, providing resources for continued commercial expansion and clinical development. Longer term, Pharming Group is also testing leniolisib in broader primary immunodeficiency populations with immune dysregulation, which could materially expand the drug’s addressable market beyond the ultra-rare APDS population if later-stage studies succeed.
Pharming Group shares remain under pressure despite expanding Joenja regulatory momentum
Pharming Group’s Nasdaq-listed American depositary receipts entered the September 25 session after two consecutive declines. The shares closed September 24 at $10.44, down 3.06%, following a 4.35% decline the previous session, although after-hours trading recovered modestly to $10.59. The stock has also remained well below its 52-week high, indicating that investors continue to weigh Joenja growth against declining RUCONEST revenue, lower full-year guidance and the costs of expanding Pharming Group’s rare-disease pipeline.
Recent clinical developments have nevertheless improved the longer-term leniolisib narrative. Canaccord Genuity reiterated a Buy rating and $38 price target following positive data from the company’s broader immune-dysregulation program, although analyst price targets are opinions rather than reliable indicators of future performance.
The Priority Review adds another near-term regulatory catalyst without fundamentally changing the principal question surrounding Joenja. Pharming Group has already demonstrated that leniolisib can improve key biological manifestations of APDS in children; the FDA now needs to determine whether the lower-dose pharmacology is sufficiently characterized to safely extend treatment to smaller patients.
If approved, Joenja would become available in the United States to eligible APDS patients aged four years and older weighing at least 13 kilograms, significantly broadening the pediatric label after a regulatory process that was temporarily derailed by dosing concerns. The January 30 decision will determine whether Pharming Group has successfully closed that final lower-weight gap.
